Quantcast
Home > Quotes > ATXI

Avenue Therapeutics, Inc. Common Stock (ATXI) Quote & Summary Data

ATXI 
$4.7315
*  
0.2585
5.18%
Get ATXI Alerts
*Delayed - data as of Nov. 15, 2018 11:27 ET  -  Find a broker to begin trading ATXI now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ATXI Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 4.75 / $ 4.88
1 Year Target
11
Today's High / Low
$ 5.15 / $ 4.66
Share Volume
50,765
50 Day Avg. Daily Volume
97,743
Previous Close
$ 4.99
52 Week High / Low
$ 5.90 / $ 2.0804
Market Cap
49,938,238
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.13

Intraday Chart

Shares Traded

Share Volume:
50,765
50 Day Avg. Daily Volume:
97,743

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.36

Trading Range

The current last sale of $4.7315 is 127.43% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.15 $ 5.90
 Low: $ 4.66 $ 2.0804

Company Description (as filed with the SEC)

We are a specialty pharmaceutical company that acquires, licenses, develops and commercializes products principally for use in the acute/intensive care hospital setting. Our product candidate is intravenous (IV) Tramadol, for the treatment of moderate to moderately severe post-operative pain. In 2016, we completed a pharmacokinetic (PK) study for IV Tramadol in healthy volunteers as well as an end of phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). In the third quarter of 2017, we initiated a Phase 3 development program of IV Tramadol for the management of post-operative pain. Under the terms of certain agreements described herein, we have an exclusive license to develop and commercialize IV Tramadol in the United States. We plan to seek additional products to develop in the acute/intensive care hospital market in addition to IV Tramadol.  ... More ...  


Risk Grade

Where does ATXI fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 5.04
Open Date:
Nov. 15, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x